Rural New England Health Study (Phase 2) (NCT05466331) | Clinical Trial Compass
UnknownNot Applicable
Rural New England Health Study (Phase 2)
United States220 participantsStarted 2022-05-18
Plain-language summary
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New England. The intervention aims to reach rural opioid injectors with HCV and to fill service gaps identified around access to syringe services and HCV testing and treatment, while limiting the burden on local partners. If effective, this mobile model of HCV telehealth integrated with syringe services will provide a promising approach for local public health authorities seeking to curb opioid injection, syringe sharing and HCV rates in rural America, and reduce the risk environment for HIV outbreaks in those communities.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Current or past history of drug injection;
✓. Health insurance that will cover HCV medications (study staff will work with those who are eligible but have not signed up for insurance prior to study enrollment)
✓. Lives in one of the study counties in NH and VT, and plans to remain in the study region for the next 12 months;
✓. Age 18 years or older;
✓. Speaks English;
✓. Capacity to voluntarily provide informed consent;
✓. Will accept randomized assignment, and participate in follow-up over 12 months;
✓. Will provide releases to access community medical records;
Exclusion criteria
✕. Unable to obtain venous blood sample for mandatory laboratory testing
✕. Significant renal failure (eGFR 30 mL/min/1.73m2 or less, or end-stage renal disease requiring dialysis);
✕. Decompensated cirrhosis, as manifested by liver fibrosis on elastography (FibroScan) and/or Fibrosure blood test plus at least one of the following symptoms: